阿司匹林极少用于Lynch综合征患者的结直肠癌预防
Aspirin rarely used for colorectal cancer prevention
德国一项对539名Lynch综合征患者的调查显示,仅6.9%专门服用阿司匹林用于癌症预防,尽管约97%知晓筛查建议。CaPP3研究提示每日100毫克低剂量或具类似预防效果且出血等副作用更少,但作者提醒结果仍需谨慎解读。相关论文发表于The Lancet Gastroenterology & Hepatology。
调查显示Lynch综合征患者对阿司匹林预防使用率低,却对新型预防方案态度开放,提示证据转化为临床实践需加强沟通。
People with Lynch syndrome have a significantly increased risk of developing colorectal cancer and other types of cancer due to a hereditary predisposition. The CAPP2 study had already shown in this high-risk group that acetylsalicylic acid can significantly reduce the long-term risk of colorectal cancer. The study examined a comparatively high daily dose of 600 milligrams. The recently published international CaPP3 study now suggests that even a lower dose of 100 milligrams daily could have a similar cancer-preventive effect while causing fewer side effects, particularly bleeding complications. The research is published in The Lancet Gastroenterology & Hepatology journal.
"Since the statistical criteria for formal equivalence between the two studies were not met in all analyses, the results should still be interpreted with some caution," says corresponding author Dr. Robert Hüneburg, a senior physician at Medical Clinic I at the UKB, who also conducts research at the University of Bonn. "However, the results of the CaPP3 study suggest that 100 mg daily could be a practical and better-tolerated option for many patients."
Bonn survey conducted before CaPP3 publication
The survey of 539 people with Lynch syndrome from across Germany was designed before the publication of the CaPP3 results and conducted between December 2025 and February 2026. It therefore reflects the use of acetylsalicylic acid based on the scientific evidence available at that time. "Future studies must show whether the new findings on lower dosages will contribute to acetylsalicylic acid being used more frequently for cancer prevention," says Hüneburg.
The Bonn findings reveal a strong awareness of prevention: About 97% of respondents are familiar with the specific screening recommendations, and nearly all undergo regular colonoscopies. Nevertheless, only 10.4% reported currently taking acetylsalicylic acid. Only 6.9% of the entire group specifically used acetylsalicylic acid for cancer prevention in Lynch syndrome. "The main reasons cited were a lack of prior engagement with the topic, concerns about side effects and uncertainty regarding the scientific evidence," says Dr. Anne-Sophie Layritz, co-first author of the study and an assistant physician at Medical Clinic I at the UKB.
At the same time, there was a high level of openness toward new preventive approaches. About three-quarters of those surveyed could, in principle, imagine participating in a study on a preventive mRNA cancer vaccine. After receiving additional information, this proportion rose to about 80%. More than 92% stated that they would want to receive such a vaccine if it were approved in the future.
A majority also accepted the possibility of being assigned to a placebo group and the risk of side effects. "These results show just how great the interest is among those affected in innovative prevention options and in actively participating in research," says co-first author Nicola Reents of SemiColon.
Implementation gap in care
The results of the LYNX study thus do not indicate any fundamental reluctance toward cancer prevention. Rather, there is a significant implementation gap between scientific evidence, medical counseling and actual use. According to the authors, people with Lynch syndrome are very open to prevention and new research approaches. However, early, understandable and structured information, as well as an individualized assessment of benefits and risks, are crucial.
Support from the centers of the German Consortium Familial Colorectal Cancer and collaboration with the self-help organization SemiColon were central to the project. Through this network, many affected individuals were reached, and the research questions and results could be put in context from the patients' perspective. Reents of SemiColon is also a co-first author of the publication. "The project is thus a very good example of research that is conducted not just about, but together with, those affected," emphasizes Hüneburg.
Publication details
Anne-Sophie Layritz et al, The implementation gap in aspirin chemoprevention for Lynch syndrome, The Lancet Gastroenterology & Hepatology (2026). DOI: 10.1016/s2468-1253(26)00216-5
Journal information: The Lancet Gastroenterology & Hepatology
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Aspirin rarely used for colorectal cancer prevention (2026, October 10) retrieved 10 October 2026 from https://medicalxpress.com/news/2026-10-aspirin-rarely-colorectal-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com